Cocktail For Recurrent Herpetic Keratoconjunctivitis: Combination Of Subconjunctival And Topical Bevacizumab,
Published 2023 - 41st Congress of the ESCRS
Reference: PO0816 | DOI: 10.82333/tfrk-5m87
Authors: Yolanda Fernandez-Barrientos* 1 , Adrian Robles-Garcia 1 , Encarnación Jimenez-Rodriguez 1 , Jose Luis Gonzalez-de-Gor-Crooke 1 , Jose Manuel Sandoval-Codoni 1 , Rafael Luque-Aranda 1
1Ophthalmology,Hospital Universitario Virgen de la Victoria,Malaga,Spain
Topical and conjunctival bevacizumab for corneal vascularization.
A 43-year-old male complains of foreign body sensation in his left eye and recurrent conjunctivitis episodes. A slit lamp
examination of the left eye revealed a temporal chronic deep corneal neovascularization(CNV) associated inflammatory stromal
lesion-positive fluorescein staining. Recurrent herpetic keratoconjunctivitis was diagnosticated.
Subconjunctival injection of bevacizumab 0.05 ml (1.25 mg) (Avastin, Roche Pharma, Germany) was done near the limbus where maximum neovascularization was seen and topical eye drops (5mg/ml) were used due to the long evolution of the CNV.
The recurrences of keratoconjunctivitis with epithelial disappeared and repeated injections were required, due to moderate remission of the area and caliber of the neovascular vessel area and caliber
The literature suggests that bevacizumab appears to be a safe and effective modality in the treatment of chronic CNV with repeated bevacizumab injections. No short-term adverse effects have been observed with the use of intrastromal, subconjunctival, or topical bevacizumab.